Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverterâ Defibrillators in the Cardiovascular Research Network

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/143721/1/jah33061_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/143721/2/jah33061.pd

High resolution haptic sensing system in virtual reality

One of the ways to know and to determine one\u27s shape is through the sense of touch. Even in the absence of vision, it would still be possible to recognize one\u27s shape by simply touching the surface. However, there are things that you cannot touch. And even though the use of vision may be difficult, you can still identify the object\u27s shape or figure by using devices such as cameras. In this study, the researchers aim to feel and identify the shape of an object that you cannot see, and more importantly, an object that does not physically exist. This thesis is making use of human\u27s haptic sense in order to feel the shape of the object without it being physically present. The shape of the objects coming from the computer will be felt by the user through a matrix of tactile pins. Each pin corresponds to one motor which is controlled by a motor driver. Data information sent to the motor driver will come from the microcontroller which is connected to the computer via RS232

A business plan on the Pink Corporation

Executive Summary. Pink Corporation is a bag manufacturing company that aims to combine fashion and convenience through the creation of high quality and reasonably priced products. The corporation was founded by ten young women whose interest in fashion inspired them to establish a business in the fashion industry. Pink Corporation\u27s primary objective is to change the stereotypical view that women are weak through the creation of products that would offer women of all ages both convenience and style. The company further believes that employee empowerment is the key to customer satisfaction and company success. Tuck-It-In is the name of the product because it already gives an idea as to how the bag works. Tuck-It-In is a bag made from attractive and durable nylon material, which is known to be a water-resistant fabric. This material also makes it easier for the bag to be folded up, so that it can be placed inside its front pocket. Tuck-It-In is especially designed for practicality purposes. The target market of the product is female college and high school students, ages 13 to 22. The monthly demand was found to be 285 units, which is higher than the capacity per month of 56 units. The company aims to provide benefits to the consumers, such as convenience and practicality, through the product and the services that augment it. Tuck-It-In is priced at P 270 but it can still be offered at a lower price through discounts and promotions for selected buyers. The company will employ a direct marketing channel but also plans to use intermediaries in the second trimester of operations. Advertising will also be in the form of leaflets, posters, banners, and a company website. The proponents used the assembly line method since some of the proponents are more skilled than the others. Therefore, the assignment of tasks depends on the skills of the laborers. Based on the time and motion study done, it was computed that the maximum, minimum, and average capacity per production were 22.46,5.22, and 13.84 units respectively while the computed production cost amounted to P 136.27. The plant site is located at # 8 Rainbow St., Marikina City. It is a bag and wallet factory owned by Mr. Benito Lim. There will be three workstations that will be situated only in a portion of the entire factory. The group will try to observe the policy of doing things right the first time all the time through applying quality control in the manufacturing process whenever necessary. The operating schedule of the company will be from 7:30 am - 5:30 p.m. every Saturday wherein a projected output of 520 units was computed. The company expects a net income of P 66890.73 in ten months of operation. In order to break-even, the company has to sell 158 units

Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network

BACKGROUND: Primary prevention implantable cardioverter-defibrillators (ICDs) reduce mortality in selected patients with left ventricular systolic dysfunction by delivering therapies (antitachycardia pacing or shocks) to terminate potentially lethal arrhythmias; inappropriate therapies also occur. We assessed device therapies among adults receiving primary prevention ICDs in 7 healthcare systems. METHODS AND RESULTS: We linked medical record data, adjudicated device therapies, and the National Cardiovascular Data Registry ICD Registry. Survival analysis evaluated therapy probability and predictors after ICD implant from 2006 to 2009, with attention to Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups: left ventricular ejection fraction, 31% to 35%; nonischemic cardiomyopathymonths\u27 duration; and New York Heart Association class IV heart failure with cardiac resynchronization therapy defibrillator. Among 2540 patients, 35% wereold, 26% were women, and 59% were white. During 27 (median) months, 738 (29%) received ≥1 therapy. Three-year therapy risk was 36% (appropriate, 24%; inappropriate, 12%). Appropriate therapy was more common in men (adjusted hazard ratio [HR], 1.84; 95% confidence interval [CI], 1.43-2.35). Inappropriate therapy was more common in patients with atrial fibrillation (adjusted HR, 2.20; 95% CI, 1.68-2.87), but less common among patients ≥65 years old versus younger (adjusted HR, 0.72; 95% CI, 0.54-0.95) and in recent implants (eg, in 2009 versus 2006; adjusted HR, 0.66; 95% CI, 0.46-0.95). In Centers for Medicare and Medicaid Services Coverage With Evidence Development analysis, inappropriate therapy was less common with cardiac resynchronization therapy defibrillator versus single chamber (adjusted HR, 0.55; 95% CI, 0.36-0.84); therapy risk did not otherwise differ for Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups. CONCLUSIONS: In this community cohort of primary prevention patients receiving ICD, therapy delivery varied across demographic and clinical characteristics, but did not differ meaningfully for Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups

Longitudinal study of implantable cardioverter-defibrillators: methods and clinical characteristics of patients receiving implantable cardioverter-defibrillators for primary prevention in contemporary practice

Background- Implantable cardioverter-defibrillators (ICDs) are increasingly used for primary prevention after randomized, controlled trials demonstrating that they reduce the risk of death in patients with left ventricular systolic dysfunction. The extent to which the clinical characteristics and long-term outcomes of unselected, community-based patients with left ventricular systolic dysfunction undergoing primary prevention ICD implantation in a real-world setting compare with those enrolled in the randomized, controlled trials is not well characterized. This study is being conducted to address these questions. Methods and Results- The study cohort includes consecutive patients undergoing primary prevention ICD placement between January 1, 2006 and December 31, 2009 in 7 health plans. Baseline clinical characteristics were acquired from the National Cardiovascular Data Registry ICD Registry. Longitudinal data collection is underway, and will include hospitalization, mortality, and resource use from standardized health plan data archives. Data regarding ICD therapies will be obtained through chart abstraction and adjudicated by a panel of experts in device therapy. Compared with the populations of primary prevention ICD therapy randomized, controlled trials, the cohort (n=2621) is on average significantly older (by 2.5-6.5 years), more often female, more often from racial and ethnic minority groups, and has a higher burden of coexisting conditions. The cohort is similar, however, to a national population undergoing primary prevention ICD placement. Conclusions- Patients undergoing primary prevention ICD implantation in this study differ from those enrolled in the randomized, controlled trials that established the efficacy of ICDs. Understanding a broad range of health outcomes, including ICD therapies, will provide patients, clinicians, and policy makers with contemporary data to inform decision-making